ADHD Medication Trends in Turkey: 2009-2013
Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the...
Gespeichert in:
| Veröffentlicht in: | Journal of attention disorders 2017-12, Vol.21 (14), p.1192-1197 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1197 |
|---|---|
| container_issue | 14 |
| container_start_page | 1192 |
| container_title | Journal of attention disorders |
| container_volume | 21 |
| creator | Öner, Özgür Yilmaz, Esra Şafak Karadağ, Hasan Vural, Mert Vural, Elif Hilal Akbulat, Akif Gürsöz, Hakkı Türkçapar, Hakan Kerman, Saim |
| description | Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the November 2008 to October 2013 period. Defined daily dose (DDD) of each drug was calculated according to WHO definitions and time-series analysis was conducted. Results: There was a significant seasonal effect for prescription of all drugs. Annual use of ADHD medications increased 2.18 times for all ADHD medications combined. DDDs per 1,000 population per day for all ADHD medications were 0.28 in 2009, 0.41 in 2010, 0.52 in 2011, and 0.59 in 2012. OROS MPH represented almost 75% of all ADHD medication utilization. Conclusion: As reported from several other countries, ADHD medication use increased in Turkey. Results suggested that over- and underdiagnosis might be seen at the same time. |
| doi_str_mv | 10.1177/1087054714523129 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826580933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1087054714523129</sage_id><sourcerecordid>1826580933</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-e1a7c24382908578c4429131ca078d1cffab5ca7bad981fb60f11925b1a3cbd83</originalsourceid><addsrcrecordid>eNp1kM1PAjEQxRujEUTvnsweTUx1ph-0642AignGC56bbrdrFmEXW_bAf08J6MHE07xkfu9N5hFyjXCPqNQDglYghUIhGUeWn5A-SqkoMjE8TTqt6X7fIxcxLgC4Uoqdkx4TUgqW6z65G02mk-zNl7Wzm7ptsnnwTRmzOqkufPntY8YAcsoA-SU5q-wy-qvjHJCP56f5eEpn7y-v49GMOs7Vhnq0yjHBNctBS6WdSKeQo7OgdImuqmwhnVWFLXONVTGECjFnskDLXVFqPiC3h9x1aL87HzdmVUfnl0vb-LaLBjUbSg055wmFA-pCG2PwlVmHemXD1iCYfUXmb0XJcnNM74qVL38NP50kgB6AaD-9WbRdaNK3_wfuAF16aXM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826580933</pqid></control><display><type>article</type><title>ADHD Medication Trends in Turkey: 2009-2013</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Öner, Özgür ; Yilmaz, Esra Şafak ; Karadağ, Hasan ; Vural, Mert ; Vural, Elif Hilal ; Akbulat, Akif ; Gürsöz, Hakkı ; Türkçapar, Hakan ; Kerman, Saim</creator><creatorcontrib>Öner, Özgür ; Yilmaz, Esra Şafak ; Karadağ, Hasan ; Vural, Mert ; Vural, Elif Hilal ; Akbulat, Akif ; Gürsöz, Hakkı ; Türkçapar, Hakan ; Kerman, Saim</creatorcontrib><description>Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the November 2008 to October 2013 period. Defined daily dose (DDD) of each drug was calculated according to WHO definitions and time-series analysis was conducted. Results: There was a significant seasonal effect for prescription of all drugs. Annual use of ADHD medications increased 2.18 times for all ADHD medications combined. DDDs per 1,000 population per day for all ADHD medications were 0.28 in 2009, 0.41 in 2010, 0.52 in 2011, and 0.59 in 2012. OROS MPH represented almost 75% of all ADHD medication utilization. Conclusion: As reported from several other countries, ADHD medication use increased in Turkey. Results suggested that over- and underdiagnosis might be seen at the same time.</description><identifier>ISSN: 1087-0547</identifier><identifier>EISSN: 1557-1246</identifier><identifier>DOI: 10.1177/1087054714523129</identifier><identifier>PMID: 24554298</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adrenergic Uptake Inhibitors - administration & dosage ; Atomoxetine Hydrochloride - administration & dosage ; Atomoxetine Hydrochloride - therapeutic use ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Attention Deficit Disorder with Hyperactivity - epidemiology ; Central Nervous System Stimulants - administration & dosage ; Central Nervous System Stimulants - therapeutic use ; Child ; Databases, Factual ; Delayed-Action Preparations ; Drug Administration Schedule ; Drug Prescriptions ; Female ; Humans ; Male ; Methylphenidate - administration & dosage ; Methylphenidate - therapeutic use ; Practice Patterns, Physicians' - statistics & numerical data ; Practice Patterns, Physicians' - trends ; Seasons ; Treatment Outcome ; Turkey - epidemiology</subject><ispartof>Journal of attention disorders, 2017-12, Vol.21 (14), p.1192-1197</ispartof><rights>The Author(s) 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-e1a7c24382908578c4429131ca078d1cffab5ca7bad981fb60f11925b1a3cbd83</citedby><cites>FETCH-LOGICAL-c337t-e1a7c24382908578c4429131ca078d1cffab5ca7bad981fb60f11925b1a3cbd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1087054714523129$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1087054714523129$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24554298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Öner, Özgür</creatorcontrib><creatorcontrib>Yilmaz, Esra Şafak</creatorcontrib><creatorcontrib>Karadağ, Hasan</creatorcontrib><creatorcontrib>Vural, Mert</creatorcontrib><creatorcontrib>Vural, Elif Hilal</creatorcontrib><creatorcontrib>Akbulat, Akif</creatorcontrib><creatorcontrib>Gürsöz, Hakkı</creatorcontrib><creatorcontrib>Türkçapar, Hakan</creatorcontrib><creatorcontrib>Kerman, Saim</creatorcontrib><title>ADHD Medication Trends in Turkey: 2009-2013</title><title>Journal of attention disorders</title><addtitle>J Atten Disord</addtitle><description>Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the November 2008 to October 2013 period. Defined daily dose (DDD) of each drug was calculated according to WHO definitions and time-series analysis was conducted. Results: There was a significant seasonal effect for prescription of all drugs. Annual use of ADHD medications increased 2.18 times for all ADHD medications combined. DDDs per 1,000 population per day for all ADHD medications were 0.28 in 2009, 0.41 in 2010, 0.52 in 2011, and 0.59 in 2012. OROS MPH represented almost 75% of all ADHD medication utilization. Conclusion: As reported from several other countries, ADHD medication use increased in Turkey. Results suggested that over- and underdiagnosis might be seen at the same time.</description><subject>Adrenergic Uptake Inhibitors - administration & dosage</subject><subject>Atomoxetine Hydrochloride - administration & dosage</subject><subject>Atomoxetine Hydrochloride - therapeutic use</subject><subject>Attention Deficit Disorder with Hyperactivity - drug therapy</subject><subject>Attention Deficit Disorder with Hyperactivity - epidemiology</subject><subject>Central Nervous System Stimulants - administration & dosage</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Child</subject><subject>Databases, Factual</subject><subject>Delayed-Action Preparations</subject><subject>Drug Administration Schedule</subject><subject>Drug Prescriptions</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Methylphenidate - administration & dosage</subject><subject>Methylphenidate - therapeutic use</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Practice Patterns, Physicians' - trends</subject><subject>Seasons</subject><subject>Treatment Outcome</subject><subject>Turkey - epidemiology</subject><issn>1087-0547</issn><issn>1557-1246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1PAjEQxRujEUTvnsweTUx1ph-0642AignGC56bbrdrFmEXW_bAf08J6MHE07xkfu9N5hFyjXCPqNQDglYghUIhGUeWn5A-SqkoMjE8TTqt6X7fIxcxLgC4Uoqdkx4TUgqW6z65G02mk-zNl7Wzm7ptsnnwTRmzOqkufPntY8YAcsoA-SU5q-wy-qvjHJCP56f5eEpn7y-v49GMOs7Vhnq0yjHBNctBS6WdSKeQo7OgdImuqmwhnVWFLXONVTGECjFnskDLXVFqPiC3h9x1aL87HzdmVUfnl0vb-LaLBjUbSg055wmFA-pCG2PwlVmHemXD1iCYfUXmb0XJcnNM74qVL38NP50kgB6AaD-9WbRdaNK3_wfuAF16aXM</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Öner, Özgür</creator><creator>Yilmaz, Esra Şafak</creator><creator>Karadağ, Hasan</creator><creator>Vural, Mert</creator><creator>Vural, Elif Hilal</creator><creator>Akbulat, Akif</creator><creator>Gürsöz, Hakkı</creator><creator>Türkçapar, Hakan</creator><creator>Kerman, Saim</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201712</creationdate><title>ADHD Medication Trends in Turkey: 2009-2013</title><author>Öner, Özgür ; Yilmaz, Esra Şafak ; Karadağ, Hasan ; Vural, Mert ; Vural, Elif Hilal ; Akbulat, Akif ; Gürsöz, Hakkı ; Türkçapar, Hakan ; Kerman, Saim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-e1a7c24382908578c4429131ca078d1cffab5ca7bad981fb60f11925b1a3cbd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adrenergic Uptake Inhibitors - administration & dosage</topic><topic>Atomoxetine Hydrochloride - administration & dosage</topic><topic>Atomoxetine Hydrochloride - therapeutic use</topic><topic>Attention Deficit Disorder with Hyperactivity - drug therapy</topic><topic>Attention Deficit Disorder with Hyperactivity - epidemiology</topic><topic>Central Nervous System Stimulants - administration & dosage</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Child</topic><topic>Databases, Factual</topic><topic>Delayed-Action Preparations</topic><topic>Drug Administration Schedule</topic><topic>Drug Prescriptions</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Methylphenidate - administration & dosage</topic><topic>Methylphenidate - therapeutic use</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Practice Patterns, Physicians' - trends</topic><topic>Seasons</topic><topic>Treatment Outcome</topic><topic>Turkey - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Öner, Özgür</creatorcontrib><creatorcontrib>Yilmaz, Esra Şafak</creatorcontrib><creatorcontrib>Karadağ, Hasan</creatorcontrib><creatorcontrib>Vural, Mert</creatorcontrib><creatorcontrib>Vural, Elif Hilal</creatorcontrib><creatorcontrib>Akbulat, Akif</creatorcontrib><creatorcontrib>Gürsöz, Hakkı</creatorcontrib><creatorcontrib>Türkçapar, Hakan</creatorcontrib><creatorcontrib>Kerman, Saim</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of attention disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Öner, Özgür</au><au>Yilmaz, Esra Şafak</au><au>Karadağ, Hasan</au><au>Vural, Mert</au><au>Vural, Elif Hilal</au><au>Akbulat, Akif</au><au>Gürsöz, Hakkı</au><au>Türkçapar, Hakan</au><au>Kerman, Saim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ADHD Medication Trends in Turkey: 2009-2013</atitle><jtitle>Journal of attention disorders</jtitle><addtitle>J Atten Disord</addtitle><date>2017-12</date><risdate>2017</risdate><volume>21</volume><issue>14</issue><spage>1192</spage><epage>1197</epage><pages>1192-1197</pages><issn>1087-0547</issn><eissn>1557-1246</eissn><abstract>Objective: To investigate the change of ADHD medication prescriptions in Turkey between 2009 and 2013. Method: Consumption data of ADHD medications, immediate release (IR) methylphenidate (MPH; Ritalin), OROS MPH (Concerta), and atomoxetine (Strattera) were obtained from IMS Health database for the November 2008 to October 2013 period. Defined daily dose (DDD) of each drug was calculated according to WHO definitions and time-series analysis was conducted. Results: There was a significant seasonal effect for prescription of all drugs. Annual use of ADHD medications increased 2.18 times for all ADHD medications combined. DDDs per 1,000 population per day for all ADHD medications were 0.28 in 2009, 0.41 in 2010, 0.52 in 2011, and 0.59 in 2012. OROS MPH represented almost 75% of all ADHD medication utilization. Conclusion: As reported from several other countries, ADHD medication use increased in Turkey. Results suggested that over- and underdiagnosis might be seen at the same time.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>24554298</pmid><doi>10.1177/1087054714523129</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0547 |
| ispartof | Journal of attention disorders, 2017-12, Vol.21 (14), p.1192-1197 |
| issn | 1087-0547 1557-1246 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826580933 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Adrenergic Uptake Inhibitors - administration & dosage Atomoxetine Hydrochloride - administration & dosage Atomoxetine Hydrochloride - therapeutic use Attention Deficit Disorder with Hyperactivity - drug therapy Attention Deficit Disorder with Hyperactivity - epidemiology Central Nervous System Stimulants - administration & dosage Central Nervous System Stimulants - therapeutic use Child Databases, Factual Delayed-Action Preparations Drug Administration Schedule Drug Prescriptions Female Humans Male Methylphenidate - administration & dosage Methylphenidate - therapeutic use Practice Patterns, Physicians' - statistics & numerical data Practice Patterns, Physicians' - trends Seasons Treatment Outcome Turkey - epidemiology |
| title | ADHD Medication Trends in Turkey: 2009-2013 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T01%3A25%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ADHD%20Medication%20Trends%20in%20Turkey:%202009-2013&rft.jtitle=Journal%20of%20attention%20disorders&rft.au=%C3%96ner,%20%C3%96zg%C3%BCr&rft.date=2017-12&rft.volume=21&rft.issue=14&rft.spage=1192&rft.epage=1197&rft.pages=1192-1197&rft.issn=1087-0547&rft.eissn=1557-1246&rft_id=info:doi/10.1177/1087054714523129&rft_dat=%3Cproquest_cross%3E1826580933%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826580933&rft_id=info:pmid/24554298&rft_sage_id=10.1177_1087054714523129&rfr_iscdi=true |